Publications
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Clinical genitourinary cancer. 2014. PMID: 25557266
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Clinical genitourinary cancer. 2014. PMID: 25557266
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Clinical genitourinary cancer. 2014. PMID: 25557266
Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. PMID: 25492084
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer cell. 2014. PMID: 28898680
Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, Isono K, Koseki H, Sekeres MA, Saunthararajah Y, Barnard J, Lindner D, Rogers HJ, Tiu RV. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. Journal of hematology & oncology. 2014. PMID: 25481243
James L. Rubenstein, Paul Formaker, Xiaomin Wang, Nianhang Chen, Michael Seider, Pamela Munster, Bertil Damato. Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma. Blood. 2014. PMID:
Katherine A Minson, Catherine C Smith, Alisa B. Lee-Sherick, Deborah DeRyckere, Elisabeth Lasater, Amanda A. Hill, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Neil P. Shah, Douglas K. Graham. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. Blood. 2014. PMID:
Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC cancer. 2014. PMID: 25471129
Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2014. PMID: 25469673
Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2014. PMID: 25469673
Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM. Economics of Malignant Gliomas: A Critical Review. Journal of oncology practice. 2014. PMID: 25466707
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2014. PMID: 25505215
Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, Brookes E, Cherry AB, Demirbas D, Tsankov AM, Zon LI, Rubin LL, Feinberg AP, Meissner A, Cowan CA, Daley GQ. A comparison of non-integrating reprogramming methods. Nature biotechnology. 2014. PMID: 25437882
Cinar P, Calkins SM, Venook AP, Kelley RK. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer research. 2014. PMID: 25503172
Biran N, Ely S, Chari A. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Current hematologic malignancy reports. 2014. PMID: 25224462
Cinar P, Calkins SM, Venook AP, Kelley RK. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer research. 2014. PMID: 25503172
Ely S, Biran N, Chari A. What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series. Current hematologic malignancy reports. 2014. PMID: 25277219
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nature reviews. Molecular cell biology. 2014. PMID: 25415508
Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. Volume 5 of Issue 6 Journal of gastrointestinal oncology. 2014. PMID: 25436138